WASHINGTON, D.C. — After weeks of testimony, the federal hearing that could reshape the future of the U.S. cannabis industry has officially ended. Now marijuana businesses across Michigan and Ohio are waiting to learn whether the biggest federal cannabis policy change in more than 50 years will finally become reality—or whether the process will drag
WASHINGTON DC — The federal government spent the opening day of historic marijuana rescheduling hearings Monday making arguments that would have been almost unimaginable just a few years ago: cannabis has accepted medical use, carries lower abuse potential than drugs in Schedule I and II, and presents a lower overdose risk than opioids and alcohol.
Cannabis Industry Says It Has No Voice In Upcoming DEA Hearing That Could Affect Taxes, Research And Future Growth LANSING – Michigan's medical marijuana market has nearly vanished, generating just $322,350 in sales during May, according to the Michigan Cannabis Regulatory Agency. Yet a federal debate centered on marijuana's medical value could have sweeping consequences
NORML says agency misapplied federal law by excluding all supporters of cannabis reform from June 29 proceedings WASHINGTON, DC - The National Organization for the Reform of Marijuana Laws (NORML) is accusing the Drug Enforcement Administration of creating a one-sided hearing process that could influence the future of federal marijuana policy and the financial outlook
WASHINGTON DC - The Drug Enforcement Administration has invited only opponents of marijuana reform to participate in a June 29 hearing that could influence the future of federal cannabis policy, a decision that is drawing criticism from legalization advocates, consumer groups and state-licensed marijuana businesses that were excluded from the proceedings. The hearing, scheduled to
COLUMBUS - A shift in federal marijuana policy could give Ohio’s cannabis industry a financial edge—and potentially draw more customers across the border from Michigan. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, easing federal restrictions for part of the industry. It’s not full legalization. But for operators,
WASHINGTON DC - A major federal shift in marijuana policy is underway—but for Michigan’s booming cannabis industry, the impact is more nuanced than headlines suggest. The Trump administration announced Thursday it is moving to reclassify marijuana from a Schedule I drug to Schedule III under the Drug Enforcement Administration framework—formally recognizing medical value for the
